
Divi’s Laboratories reported higher quarterly revenue and profit as its shares extended a rally and its market value crossed ₹3 trillion.
Divi’s Laboratories’ market capitalisation crossed ₹3 trillion on Monday after the company reported strong earnings for the quarter ended September 2026. Its shares reached a record ₹11,818 in intraday trading, extending a rally that had lifted the stock 32% over 12 trading days, according to Business Standard.
As of 04:54 UTC on Monday, the shares traded at ₹11,726, up 5.67% since the previous close. Business Standard reported that Divi’s had a market value of ₹3.09 trillion at 09:40 a.m.
Revenue rose 35% year on year to ₹3,676 crore. Custom Synthesis revenue grew 44% to ₹2,200 crore, Nutraceuticals revenue increased 13% to ₹273 crore, and Generics revenue rose 4.3% to ₹1,050 crore.
Adjusted profit after tax climbed 64% to ₹1,127 crore. EBITDA, a measure of operating earnings, increased 76.4% to ₹1,566 crore, while the margin expanded 989 basis points to 42.6%.
ICICI Securities said three large dedicated projects were in validation, with one nearing commercialisation and two expected to reach that stage in coming quarters. It also noted that pricing pressure in generics was likely to persist for several more quarters, according to the company’s management.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.